Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing, and development of more than 100 companies, including twenty-seven which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Sana Biotechnology (SANA), Unity Biotechnology (UBX); Sienna Biopharmaceuticals (SNNA); Vir Biotechnology(VIR); Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL; Ikaria; Kythera Biopharmaceuticals (KYTH); Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Prime Medicine; Beam Therapeutics (BEAM); NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); Editas (EDIT); IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); Rubius Therapeutics (RUBY); KSQ Therapeutics; WuxiNextCODE; and Everyday Learning Corporation.

Mr Nelsen is a director of Vir Bio, GRAIL, Sana Biotechnology, Beam Therapeutics, Prime Medicine, Resilience, Lyell, RBNC, Revolution Healthcare Acquisition Corp., Denali Therapeutics, Karuna Therapeutics, insitro, Maze Therapeutics, Inc., and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.